$Risk of osteoporotic fractures in new users of denosumab compared with new users of alendronate: A Danish populationbased cohort study$

Risk of osteoporotic fractures in new users of denosumab compared with new users of alendronate: A Danish populationbased cohort study

Dettagli Bibliografici
Autori principali:	Pedersen, AB, Heide-Jorgensen, U, Sorensen, HT, Prieto-Alhambra, D, Ehrenstein, V
Natura:	Conference item
Pubblicazione:	Wiley 2018

Documenti analoghi

Comparison of risk of osteoporotic fracture in Denosumab vs Alendronate treatment within 3 years of initiation
di: Pedersen, AB, et al.
Pubblicazione: (2019)

The Efficacy of Alendronate Versus Denosumab on Major Osteoporotic Fracture Risk in Elderly Patients With Diabetes Mellitus: A Danish Retrospective Cohort Study
di: Rikke Viggers, et al.
Pubblicazione: (2022-01-01)

Danish clinical quality databases – an important and untapped resource for clinical research
di: Sørensen HT, et al.
Pubblicazione: (2016-10-01)

Denosumab for the prevention of osteoporotic fractures in postmenopausal women
di: N Waugh, et al.
Pubblicazione: (2011-05-01)

Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users.
di: Eiken, P, et al.
Pubblicazione: (2017)

Reduction in fracture rates with Denosumab compared to Alendronate in treatment naïve patients: a propensity-matched ‘real world’ cohort and instrumental variable analysis.
di: Khalid, S, et al.
Pubblicazione: (2017)

Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study
di: Prieto Alhambra, D, et al.
Pubblicazione: (2016)

Prevalence of lifestyle characteristics in glucocorticoid users and non-users: a Danish population-based cross-sectional study
di: Irene Petersen, et al.
Pubblicazione: (2019-10-01)

Real-Life and RCT Participants: Alendronate Users Versus FITs' Trial Eligibility Criterion.
di: Reyes, C, et al.
Pubblicazione: (2016)

Impact of Teriparatide and Denosumab on Clinical and Radiographic Outcomes in Osteoporotic Vertebral Compression Fractures
di: Byung-Taek Kwon, et al.
Pubblicazione: (2024-08-01)

Esophageal and gastric cancer incidence and mortality in alendronate users.
di: Abrahamsen, B, et al.
Pubblicazione: (2012)

The Impact of Alendronate on Bone Mineral Density of Osteoporotic Patients
di: Hamidreza Aghaei-Meybodi, et al.
Pubblicazione: (2013-12-01)

Prevention and treatment of recurrent fractures after percutaneous vertebroplasty with denosumab in patients with osteoporotic vertebral compression fractures
di: Shouyu Xiang, et al.
Pubblicazione: (2025-01-01)

Use of Thiazolidinediones and Risk of Osteoporotic Fracture: The Danish National Databases
di: Bazelier, M, et al.
Pubblicazione: (2011)

Epidemiology malignant tumors of the eye and its adnexa (populationbased study)
di: V. Merabishvili, et al.
Pubblicazione: (2016-01-01)

The marital status of disabled women in Canada: a populationbased analysis
di: Amber Savage, et al.
Pubblicazione: (2015-09-01)

Is serum pepsinogen testing necessary in populationbased screening for gastric cancer?
di: Yeon-Ji Kim, et al.
Pubblicazione: (2020-05-01)

Ibuprofen for Acute Pericarditis and Associated Cardiovascular Risks: A Danish Nationwide, Population-Based Cohort Study
di: Eika JK, et al.
Pubblicazione: (2024-11-01)

Validity of Major Osteoporotic Fracture Diagnoses in the Danish National Patient Registry
di: Clausen A, et al.
Pubblicazione: (2024-04-01)

Investigating Denosumab discontinuation in the TgRANKL osteoporotic mouse model
di: Vagelis Rinotas, et al.
Pubblicazione: (2021-04-01)

Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation
di: Sarah Davis, et al.
Pubblicazione: (2020-06-01)

Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation
di: Sarah Davis, et al.
Pubblicazione: (2020-06-01)

Effect of Denosumab or Alendronate on Vascular Calcification: Secondary Analysis of SALTIRE2 Randomized Controlled Trial
di: Jolien Geers, et al.
Pubblicazione: (2024-09-01)

Three-year experience with combined treatment with alendronate and alfacalcidol in Japanese patients with severe bone loss and osteoporotic fracture
di: Iwamoto J, et al.
Pubblicazione: (2011-06-01)

Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures
di: Javaid, M, et al.
Pubblicazione: (2019)

Fractures in users of antidepressants and anxiolytics and sedatives: effects of age and dose
di: Vestergaard, P, et al.
Pubblicazione: (2013)

Fractures in users of antidepressants and anxiolytics and sedatives: effects of age and dose.
di: Vestergaard, P, et al.
Pubblicazione: (2013)

Fractures in users of antidepressants and anxiolytics and sedatives effects of age and dose
di: Vestergaard, P, et al.
Pubblicazione: (2012)

The impact of sequential therapy from short-term teriparatide to denosumab compared with denosumab alone in patients with osteoporotic hip fracture: a 1-year follow-up study
di: Chan Ho Park, et al.
Pubblicazione: (2020-11-01)

Comparative analysis of denosumab, romosozumab, and teriparatide effects on bone density and structural integrity in osteoporotic vertebral compression fractures
di: T. Goh, et al.
Pubblicazione: (2024-01-01)

The Gradual Release of Alendronate for the Treatment of Critical Bone Defects in Osteoporotic and Control Rats
di: Hedvičáková V, et al.
Pubblicazione: (2023-02-01)

The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects.
di: Wei-Yih Chiu, et al.
Pubblicazione: (2018-01-01)

The Danish Sarcoma Database
di: Jorgensen PH, et al.
Pubblicazione: (2016-10-01)

The risk of oesophageal and gastric cancer incidence and mortality in alendronate users: National cohort study
di: Abrahamsen, B, et al.
Pubblicazione: (2011)

Intake of micronutrients among Danish adult users and non-users of dietary supplements
di: Susanne Bügel, et al.
Pubblicazione: (2011-09-01)

Cost-Effectiveness of Zoledronic Acid Versus Oral Alendronate for Postmenopausal Osteoporotic Women in China
di: Ruxu You, et al.
Pubblicazione: (2020-04-01)

Alendronate slows down aortic stenosis progression in osteoporotic patients: An observational prospective study
di: Gholamhossein Alishiri, et al.
Pubblicazione: (2020-01-01)

Denosumab Is Superior to Raloxifene in Lowering Risks of Mortality and Ischemic Stroke in Osteoporotic Women
di: Ting-Chun Liu, et al.
Pubblicazione: (2023-02-01)

An Assessment of Osteoporotic Conditions among Users and Non-Users of Warfarin: A Case-Control Study
di: Aseel Hadi Abdulameer, et al.
Pubblicazione: (2017-03-01)

Cost‐Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate‐Alone Strategies in High‐Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide
di: Takahiro Mori, et al.
Pubblicazione: (2019-11-01)